Surrozen Yönetim

Yönetim kriter kontrolleri 2/4

Surrozen CEO'su Craig Parker, Mar2018 tarihinde atandı, in görev süresi 8.5 yıldır. in toplam yıllık tazminatı $ 2.82M olup, şirket hissesi ve opsiyonları dahil olmak üzere 22.3% maaş ve 77.7% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.15% ine doğrudan sahiptir ve bu hisseler $ 364.04K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 4.6 yıl ve 5.5 yıldır.

Anahtar bilgiler

Craig Parker

İcra Kurulu Başkanı

US$2.8m

Toplam tazminat

CEO maaş yüzdesi	22.35%
CEO görev süresi	8.5yrs
CEO sahipliği	0.2%
Yönetim ortalama görev süresi	4.6yrs
Yönetim Kurulu ortalama görev süresi	5.5yrs

Son yönetim güncellemeleri

Recent updates

Analiz Makalesi • Aug 13

Analysts Just Made A Massive Upgrade To Their Surrozen, Inc. (NASDAQ:SRZN) Forecasts

Shareholders in Surrozen, Inc. ( NASDAQ:SRZN ) may be thrilled to learn that the analysts have just delivered a major...

Analiz Makalesi • Jan 06

Here's Why We're A Bit Worried About Surrozen's (NASDAQ:SRZN) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Analiz Makalesi • Jan 03

Will Surrozen (NASDAQ:SRZN) Spend Its Cash Wisely?

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Analiz Makalesi • Jun 19

Will Surrozen (NASDAQ:SRZN) Spend Its Cash Wisely?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Analiz Makalesi • Feb 12

Here's Why Surrozen (NASDAQ:SRZN) Must Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Seeking Alpha • Oct 06

Surrozen stock rises ~13% premarket on licensing deal with Boehringer Ingelheim

Surrozen (NASDAQ:SRZN) on Thursday said it had entered into a collaboration and licensing agreement with German pharmaceutical firm Boehringer Ingelheim for its antibody SZN-413 for the treatment of eye diseases. SRZN stock +12.5% to $2.43 in premarket trading. This is the first partnership that SRZN had entered for one of its compounds, the company said in a statement. As per the terms of the deal, SRZN will get an upfront payment of $12.5M from Boehringer. Boehringer will get an exclusive, worldwide license to develop SZN-413. SRZN will be eligible to get up to $586.5M in milestone payments and royalties on sales.

Seeking Alpha • Aug 11

Surrozen GAAP EPS of -$0.40 beats by $0.06

Surrozen press release (NASDAQ:SRZN): Q2 GAAP EPS of -$0.40 beats by $0.06. Cash, cash equivalents and marketable securities for the Q2 were $92.7 million

Seeking Alpha • Oct 14

Surrozen CEO Craig Parker - Biotechs Can Never Be Too Well Capitalized (Video)

Surrozen is pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration. CEO Craig Parker, an industry veteran, joined us to discuss why there's no such thing as being too well capitalized in the biotech industry. 'We were really excited to complete a SPAC PIPE transaction that funds us through some of these Phase IB milestones in 2024.'

CEO Tazminat Analizi

Craig Parker'un ücretlendirmesi Surrozen'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2026	n/a	n/a	-US$325m
Mar 31 2026	n/a	n/a	-US$335m
Dec 31 2025	US$3m	US$630k	-US$242m
Sep 30 2025	n/a	n/a	-US$94m
Jun 30 2025	n/a	n/a	-US$24m
Mar 31 2025	n/a	n/a	-US$71m
Dec 31 2024	US$2m	US$605k	-US$64m
Sep 30 2024	n/a	n/a	-US$44m
Jun 30 2024	n/a	n/a	-US$53m
Mar 31 2024	n/a	n/a	-US$38m
Dec 31 2023	US$1m	US$580k	-US$43m
Sep 30 2023	n/a	n/a	-US$35m
Jun 30 2023	n/a	n/a	-US$38m
Mar 31 2023	n/a	n/a	-US$42m
Dec 31 2022	US$2m	US$558k	-US$36m
Sep 30 2022	n/a	n/a	-US$50m
Jun 30 2022	n/a	n/a	-US$51m
Mar 31 2022	n/a	n/a	-US$50m
Dec 31 2021	US$4m	US$496k	-US$55m
Sep 30 2021	n/a	n/a	-US$51m
Jun 30 2021	n/a	n/a	-US$45m
Mar 31 2021	n/a	n/a	-US$39m
Dec 31 2020	US$554k	US$441k	-US$33m

Tazminat ve Piyasa: Craig 'nin toplam tazminatı ($USD 2.82M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 1.61M ).

Tazminat ve Kazançlar: Craig şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Craig Parker (64 yo)

8.5yrs

Görev süresi

US$2,819,017

Tazminat

Mr. Craig C. Parker, MBA, is Director of Synthekine, Inc. Mr. Parker serves as Chief Executive Officer and President since March 2018 and Director at Surrozen, Inc., since April 2018. He serves as Director...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Craig Parker	CEO, President & Director	8.5yrs	US$2.82m	0.15% $ 364.0k
Charles Williams	COO & Corporate Secretary	3.6yrs	US$1.52m	0.16% $ 365.3k
Yang Li	Executive Vice President of Research	5.7yrs	US$1.29m	0.17% $ 392.3k
K. Christopher Garcia	Co-Founder & Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Roeland Nusse	Co-Founder & Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Calvin Kuo	Co-Founder & Member of Scientific Advisor	no data	Veri yok	Veri yok
Andrew Maleki	Chief Financial Officer	less than a year	Veri yok	0.0052% $ 12.1k
Daniel Chao	VP & Head of Clinical Development	no data	Veri yok	Veri yok
Michael Lauw	Senior Vice President of Development Operations	no data	Veri yok	Veri yok
Esther Jhun	Controller	no data	Veri yok	Veri yok

4.6yrs

Ortalama Görev Süresi

57yo

Ortalama Yaş

Deneyimli Yönetim: SRZN 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4.6 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Craig Parker	CEO, President & Director	8.4yrs	US$2.82m	0.15% $ 364.0k
K. Christopher Garcia	Co-Founder & Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Roeland Nusse	Co-Founder & Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Calvin Kuo	Co-Founder & Member of Scientific Advisor	no data	Veri yok	Veri yok
Eric Bjerkholt	Independent Director	3.4yrs	US$49.17k	0% $ 0
Harold Varmus	Member of Scientific Advisors	no data	US$24.00k	Veri yok
Mace Rothenberg	Independent Director	5.4yrs	US$52.25k	0.020% $ 46.9k
Christopher Chai	Independent Director	5.4yrs	US$60.67k	0.020% $ 46.9k
Mary Haak-Frendscho	Independent Director	5.5yrs	US$51.67k	0.020% $ 46.9k
Tim Kutzkey	Independent Director	1.5yrs	US$50.13k	Veri yok
Anna Berkenblit	Independent Director	8.1yrs	US$53.25k	0.020% $ 46.9k
David Woodhouse	Independent Chairman of the Board	6yrs	US$79.17k	0.020% $ 46.9k

5.5yrs

Ortalama Görev Süresi

64yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: SRZN 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.5 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/09/10 08:50
Gün Sonu Hisse Fiyatı	2026/09/10 00:00
Kazançlar	2026/06/30
Yıllık Kazançlar	2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Surrozen, Inc. 9 Bu analistlerden 5, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Tazeen Ahmad	BofA Global Research
Steven Seedhouse	Cantor Fitzgerald & Co.
Yatin Suneja	Guggenheim Securities, LLC

Surrozen Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Insufficient new directors

Surrozen, Inc., Annual General Meeting, May 13, 2026

Surrozen, Inc./De Announces Resignation of Shao-Lee Lin from the Board of Directors, Effective January 26, 2026

Surrozen, Inc. Appoints Andrew Maleki as Principal Accounting Officer, Effective November 12, 2025

Surrozen, Inc. Announces CFO Changes

Surrozen, Inc., Annual General Meeting, May 14, 2025

Recent updates

Surrozen Submits IND Application For SZN-8141 For Treatment Of Diabetic Macular Edema

Consensus revenue estimates increase by 71%

Analysts Just Made A Massive Upgrade To Their Surrozen, Inc. (NASDAQ:SRZN) Forecasts

First half 2026 earnings: EPS and revenues exceed analyst expectations

Surrozen, Inc.(NasdaqCM:SRZN) dropped from Russell 3000E Value Benchmark

Consensus revenue estimates increase by 19%, EPS downgraded

First quarter 2026 earnings released: US$11.65 loss per share (vs US$4.54 loss in 1Q 2025)

Insufficient new directors

Surrozen, Inc., Annual General Meeting, May 13, 2026

Full year 2025 earnings: EPS and revenues miss analyst expectations

Surrozen, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Surrozen, Inc./De Announces Resignation of Shao-Lee Lin from the Board of Directors, Effective January 26, 2026

Surrozen (NASDAQ:SRZN) Is In A Good Position To Deliver On Growth Plans

New minor risk - Share price stability

Third quarter 2025 earnings released: US$8.36 loss per share (vs US$0.44 loss in 3Q 2024)

Surrozen, Inc. Appoints Andrew Maleki as Principal Accounting Officer, Effective November 12, 2025

Surrozen, Inc. Announces CFO Changes

Surrozen, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Companies Like Surrozen (NASDAQ:SRZN) Are In A Position To Invest In Growth

New minor risk - Share price stability

Surrozen, Inc., Annual General Meeting, May 14, 2025

New major risk - Negative shareholders equity

Insufficient new directors

Surrozen, Inc. announced that it expects to receive $175 million in funding from The Column Group, LLC, StemPoint Capital LP, RA Capital Management, L.P. and other investors.

New major risk - Share price stability

Companies Like Surrozen (NASDAQ:SRZN) Could Be Quite Risky

New major risk - Financial position

Here's Why We're A Bit Worried About Surrozen's (NASDAQ:SRZN) Cash Burn Situation

Price target decreased by 45% to US$33.00

Surrozen, Inc. Initiates Dosing of First Patient in Phase 1b Clinical Trial of SZN-043 for Severe Alcohol-Associated Hepatitis

Surrozen, Inc., Annual General Meeting, Jun 05, 2024

Surrozen, Inc. announced delayed annual 10-K filing

Surrozen Provides Update on the Phase 1A Clinical Trial of SZN-043 in Healthy Volunteers and Patients with Cirrhosis

Surrozen, Inc. announced that it expects to receive $17.549999 million in funding from The Column Group, LLC, Ra Capital Management, Inc.

Surrozen, Inc. Appoints Charles Williams to the Concurrent Position of Chief Operating Officer

Surrozen, Inc. Provides Corporate Update on Clinical Programs

Will Surrozen (NASDAQ:SRZN) Spend Its Cash Wisely?

New minor risk - Shareholder dilution

New major risk - Revenue and earnings growth

Surrozen, Inc. Expects to Initiate A Phase 1a Clinical Trials for SZN-043 and SZN-1326 in Moderate to Severe Alcoholic Hepatitis

New minor risk - Share price stability

Surrozen, Inc. Announces Management Changes

Nasdaq Grants Surrozen Additional 180 Calendar Day Period to Regain Compliance with the Minimum Bid Price Per Share Requirement for Continued Listing

Will Surrozen (NASDAQ:SRZN) Spend Its Cash Wisely?

Here's Why Surrozen (NASDAQ:SRZN) Must Use Its Cash Wisely

Surrozen Receives A Written Notice from Nasdaq Regarding Minimum Bid Requirement

Surrozen, Inc. (NasdaqCM:SRZN) announces an Equity Buyback for 1,310,496 shares, for $2.7 million.

Surrozen, Inc. Updates SZN-1326, SZN-043 and SZN-413 for Vascular-Associated Retinopathies, Including Diabetic Retinopathy and Diabetic Macular Edema

Price target decreased to US$12.50

Surrozen stock rises ~13% premarket on licensing deal with Boehringer Ingelheim

Surrozen Publishes Study in Translational Vision Science and Technology Demonstrating the Promise of Szn-413 in Preclinical Models of Diabetic Retinopathy

Surrozen GAAP EPS of -$0.40 beats by $0.06

Surrozen, Inc. Initiates Dosing in Phase 1 Clinical Trial of SZN-043 for Severe Alcoholic Hepatitis

Price target increased to US$19.50

Surrozen, Inc. Presents Data on Lead Therapeutic Candidates at Digestive Disease Week (DDW)

Surrozen, Inc. Initiates Dosing in Phase 1 Clinical Trial of SZN-1326 for Moderate to Severe Ulcerative Colitis

Surrozen, Inc. Presents Data Supporting Potential of SZN-413 for the Treatment of Diabetic Retinopathy At the Association for Research in Vision and Ophthalmology Annual Meeting

Surrozen CEO Craig Parker - Biotechs Can Never Be Too Well Capitalized (Video)

CEO Tazminat Analizi

CEO

Liderlik Ekibi

Yönetim Kurulu Üyeleri

Şirket Analizi ve Finansal Veri Durumu

Veri Kaynakları

Analiz Modeli ve Kar Tanesi

Endüstri ve Sektör Metrikleri

Analist Kaynakları